Dublin, Aug. 22, 2023 (GLOBE NEWSWIRE) -- The Global Psychobiotics Market Assessment 2018-2028 report has been added to ResearchAndMarkets.com's offering.
The Global Psychobiotics market is poised for remarkable growth during the forecast period spanning 2024 to 2028. This expansion is attributed to the escalating concerns surrounding mental health issues, including stress, anxiety, and sleep disorders, among others.
These challenges have prompted a surge in demand for solutions that address these concerns. Notably, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) of 2019 highlighted anxiety and depression disorders as the top two incapacitating mental diseases, ranking among the 25 primary causes of global disease burden. This impact is pronounced across genders and geographical boundaries, underscoring the need for effective interventions. Moreover, the COVID-19 pandemic and the subsequent lockdowns enforced globally in 2020-2021 have exacerbated mental health problems.
Psychobiotics: A Unique Approach to Mental Well-being
Psychobiotics, a distinctive category of probiotics, emerge as a solution for maintaining mental health. Setting them apart from typical probiotics, psychobiotics possess the capability to foster neurotransmitter synthesis, short-chain fatty acids, enteroendocrine hormones, and anti-inflammatory cytokines. This unique property allows them to serve a broader therapeutic role, spanning stress reduction, mood enhancement, and even adjunctive treatment for neurodevelopmental and neurodegenerative disorders. Common psychobiotic bacteria hail from families such as Lactobacilli, Streptococci, Bifidobacteria, Escherichia, and Enterococci. While the market currently boasts limited products, health-conscious individuals are integrating psychobiotics into their dietary habits, fueling the sector's projected growth.
Probiotics: A Solution for Anxiety and Depression
Probiotics exert influence over the microbial-gut-brain axis, impacting mood and overall health. Stress, anxiety, and depression, all characterized by emotional erosion, are closely interconnected. Prolonged anxiety can escalate into severe mental ailments like depression. Stress stems from various physically or emotionally taxing events and can transform into anxiety if unmanaged. A nuanced connection between anxiety and depression has been identified through numerous studies. For instance, Australian data revealed that 28% of clinically anxious patients concurrently experienced depression. Additionally, the gut microbiota plays an active role in mood regulation, bolstering the argument for probiotics' extended applications. Studies have shown that specific bacteria variations are linked to major depressive disorders. Probiotics influence central nervous system activity by inducing neurotransmitter production and modulating brain neurotransmitter receptors. Furthermore, they can alleviate inflammation by promoting anti-inflammatory cytokines while diminishing pro-inflammatory counterparts.
Increased Prevalence of Anxiety and Depression
Depression and anxiety disorders rank among the most prevalent mental illnesses, characterized by depleted mood and excessive worry, respectively. The World Health Organization (WHO) estimates that anxiety disorders affected 3.6% and depression impacted up to 4.4% of the global population in 2015. The COVID-19 pandemic has further accentuated these concerns. A Lancet study reported a 25.6% global rise in anxiety disorders and a 27.6% increase in depressive illnesses across both genders. Women were more impacted, with a 29.8% increase in depression prevalence and 27.9% for anxiety, compared to 21.7% in men.
Rising Consumer Awareness and Changing Preferences
Psychobiotics' potential to enhance overall bodily functions, including digestion, enhances their market prospects. Moreover, their capacity to address specific consumer needs, such as gastrointestinal and immune system support, has led to product advancements. A 2019 global poll by Kerry Group found that 62% of health-conscious Americans understood probiotics, with 32% using them in the past six months. Of those aware, 79% considered improved digestive health the most important health benefit.
Innovation and Market Segmentation
Manufacturers' efforts in introducing innovative psychobiotic products, including vegan and gluten-free options, align with changing dietary preferences and health-consciousness. These initiatives cater to a wider consumer base and further foster the adoption of psychobiotics. The market's segmentation includes psychotropic agents, form, and application. Common psychobiotic bacteria like Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, and others form the basis for categorization. Forms encompass powder, liquid/fluid, tablets, and more, while applications range from stress management to mood upliftment and sleep problems.
Dominant Players and Market Outlook
Key players in the Global Psychobiotics market include InnovixLabs, Bened Biomedical Co., Ltd., Nutrimmun GmbH, Kerry Group PLC, Sabinsa Corporation, Lallemand Health Solutions Inc., DuPont de Nemours, Inc., Uplift Food Pty. Ltd., Nature's Bounty Co. Ltd., BioGaia Group, The Life Extension Foundation, and Lifted Naturals. Their endeavors in developing innovative products align with evolving consumer needs and preferences.
Conclusion: A Promising Future for Psychobiotics
The projected growth of the Global Psychobiotics market from 2024 to 2028 stems from the escalating concerns about mental health issues, accentuated by the COVID-19 pandemic. The unique attributes of psychobiotics, their impact on mood and overall health, and the rising consumer awareness of probiotics contribute to this growth. With a focus on innovation, expanding product offerings, and strategic interventions for anxiety and depression, the psychobiotics market is poised for a transformative and promising future.
Report Scope
In this report, global psychobiotics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Psychotropic Agent
- Streptococcus
- Bifidobacterium
- Lactobacillus
- Clostridium
- Others
Form
- Powder
- Liquid/Fluid
- Tablets
- Others
Application
- Stress Management
- Mood Health & Mood Upliftment
- Depression
- Anxiety
- Sleep Problems
- Others
Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Key Topics Covered
1. Product Overview
2. Research Methodology
3. Executive Summary
4. Voice of Customer
5. Clinical Trial Analysis
6. Patents Analysis
7. Global Psychobiotics Market Outlook
8. North America Psychobiotics Market Outlook
9. Europe Psychobiotics Market Outlook
10. Asia-Pacific Psychobiotics Market Outlook
11. South America Psychobiotics Market Outlook
12. Middle East and Africa Psychobiotics Market Outlook
13. Market Dynamics
14. Market Trends & Developments
15. Competitive Landscape
16. Strategic Recommendations
A selection of companies mentioned in this report includes:
- InnovixLabs
- Bened Biomedical Co. Ltd.
- Nutrimmun GmbH
- Kerry Group PLC
- Sabinsa Corporation
- Lallemand Health Solutions Inc.
- DuPont de Nemours, Inc.
- Uplift Food Pty. Ltd.
- Nature's Bounty Co. Ltd.
- BioGaia Group
- The Life Extension Foundation
- Lifted Naturals
For more information about this report visit https://www.researchandmarkets.com/r/dbpjov
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
